AcquisitionsAug 6, 2026, 07:51 AM
argenx Commences Tender Offer to Acquire Forte Biosciences for $77.00/Share
AI Summary
argenx, through its wholly-owned subsidiary Avena Merger Sub Inc., has commenced a tender offer to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in cash. The offer is made under a merger agreement dated July 26, 2026, and Forte's Board of Directors has recommended that its stockholders accept the offer. The tender offer is set to expire on August 26, 2026, and is subject to customary conditions, including a minimum tender condition.
Key Highlights
- argenx, through Avena Merger Sub Inc., commenced a tender offer to acquire Forte Biosciences.
- The offer price is $77.00 per Share in cash, without interest.
- The tender offer is made pursuant to a Merger Agreement dated July 26, 2026.
- Forte's Board of Directors recommends stockholders accept the offer and tender their shares.
- The offer and withdrawal rights will expire at 11:59 p.m. ET on August 26, 2026.
- The offer is subject to a Minimum Condition of one more Share than 50% of total outstanding Shares.
- Following the tender offer, Forte will merge into Avena Merger Sub Inc. and become a wholly-owned subsidiary of argenx.
Price Impact
More from ARGX